Skyrizi® Intravenous (risankizumab-rzaa)

Skyrizi IV is covered only as a 3‑month induction regimen for adults (≥18) with moderately‑to‑severely active Crohn’s disease (600 mg IV at Weeks 0, 4, 8) or ulcerative colitis (1,200 mg IV at Weeks 0, 4, 8) and is limited to FDA‑approved indications (use outside induction or in patients <18 is excluded). Key requirements: prescription or consult by a gastroenterologist, documentation of diagnosis/age/intent and induction dosing, and for Crohn’s disease documentation of one prior systemic therapy (not mesalamine or a biosimilar) OR current/prior systemic corticosteroid use or contraindication, ileocolonic resection, or enterocutaneous/rectovaginal fistulas, plus any applicable safety criteria.

"Moderately to severely active Crohn's disease in adults."

Sign up to see full coverage criteria, indications, and limitations.